Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management

Cancer Letters

Volumn 379, Issue 2, 2016, Pages 198-205

  Zhang, Han ^a   Yang, Tian ^a   Wu, Mengchao ^a   Shen, Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Epidemiology; Intrahepatic cholangiocarcinoma; Risk factor; Surgery

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PANITUMUMAB; SORAFENIB;

ARTIFICIAL EMBOLIZATION; BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL DISORDER; DISEASE ASSOCIATION; HUMAN; INCIDENCE; LABORATORY TEST; LAPAROSCOPIC SURGERY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPH NODE DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PARASITOSIS; PREOPERATIVE PORTAL VEIN EMBOLIZATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; ABLATION THERAPY; BILE DUCT NEOPLASMS; BILIARY TRACT SURGERY; CHOLANGIOCARCINOMA; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

ABLATION TECHNIQUES; BILE DUCT NEOPLASMS; BILIARY TRACT SURGICAL PROCEDURES; CHOLANGIOCARCINOMA; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84978971935     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.008     Document Type: Review

References (107)

1. [1] Patel, T., Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001), 1353–1357.
2. [2] Blechacz, B., Komuta, M., Roskams, T., Gores, G.J., Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol 8 (2011), 512–522.
3. [3] Yamasaki, S., Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J. Hepatobiliary Pancreat. Surg 10 (2003), 288–291.
4. [4] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin 65 (2015), 5–29.
5. [5] Shaib, Y.H., Davila, J.A., McGlynn, K., El-Serag, H.B., Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J. Hepatol 40 (2004), 472–477.
6. [6] Patel, T., Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 2002, 10.
7. [7] Khan, S.A., Taylor-Robinson, S.D., Toledano, M.B., Beck, A., Elliott, P., Thomas, H.C., Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J. Hepatol 37 (2002), 806–813.
8. [8] Khan, S.A., Toledano, M.B., Taylor-Robinson, S.D., Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10 (2008), 77–82.
9. [9] Khan, S.A., Emadossadaty, S., Ladep, N.G., Thomas, H.C., Elliott, P., Taylor-Robinson, S.D., et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J. Hepatol 56 (2012), 848–854.
10. [10] Plentz, R.R., Malek, N.P., Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol 29 (2015), 245–252.
11. [11] Thinkhamrop, K., Khuntikeo, N., Phonjitt, P., Chamadol, N., Thinkhamrop, B., Moore, M.A., et al. Association between diabetes mellitus and fatty liver based on ultrasonography screening in the world's highest cholangiocarcinoma incidence region, northeast Thailand. Asian Pac. J. Cancer Prev 16 (2015), 3931–3936.
12. [12] Bergquist, A., von Seth, E., Epidemiology of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol 29 (2015), 221–232.
13. [13] Shin, H.R., Oh, J.K., Masuyer, E., Curado, M.P., Bouvard, V., Fang, Y.Y., et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 101 (2010), 579–585.
14. [14] Guglielmi, A., Ruzzenente, A., Valdegamberi, A., Bagante, F., Conci, S., Pinna, A.D., et al. Hepatolithiasis-associated cholangiocarcinoma: results from a multi-institutional national database on a case series of 23 patients. Eur. J. Surg. Oncol 40 (2014), 567–575.
15. [15] Zhu, Q.D., Zhou, M.T., Zhou, Q.Q., Shi, H.Q., Zhang, Q.Y., Yu, Z.P., Diagnosis and surgical treatment of intrahepatic hepatolithiasis combined with cholangiocarcinoma. World J. Surg 38 (2014), 2097–2104.
16. [16] Chen, M.F., Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J. Gastroenterol. Hepatol 14 (1999), 1144–1149.
17. [17] Claessen, M.M., Vleggaar, F.P., Tytgat, K.M., Siersema, P.D., van Buuren, H.R., High lifetime risk of cancer in primary sclerosing cholangitis. J. Hepatol 50 (2009), 158–164.
18. [18] Chapman, M.H., Webster, G.J., Bannoo, S., Johnson, G.J., Wittmann, J., Pereira, S.P., Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur. J. Gastroenterol. Hepatol 24 (2012), 1051–1058.
19. [19] Rizvi, S., Eaton, J.E., Gores, G.J., Primary sclerosing cholangitis as a pre-malignant biliary tract disease: surveillance and management. Clin. Gastroenterol. Hepatol, 2015, 10.1016/j.cgh.2015.05.035 Epub ahead of print.
20. [20] Tyson, G.L., El-Serag, H.B., Risk factors for cholangiocarcinoma. Hepatology 54 (2011), 173–184.
21. [21] Boberg, K.M., Bergquist, A., Mitchell, S., Pares, A., Rosina, F., Broome, U., et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand. J. Gastroenterol 37 (2002), 1205–1211.
22. [22] Melum, E., Karlsen, T.H., Schrumpf, E., Bergquist, A., Thorsby, E., Boberg, K.M., et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 47 (2008), 90–96.
23. [23] Khan, S.A., Thomas, H.C., Davidson, B.R., Taylor-Robinson, S.D., Cholangiocarcinoma. Lancet 366 (2005), 1303–1314.
24. [24] Lipsett, P.A., Pitt, H.A., Colombani, P.M., Boitnott, J.K., Cameron, J.L., Choledochal cyst disease. A changing pattern of presentation. Ann. Surg 220 (1994), 644–652.
25. [25] Soares, K.C., Kim, Y., Spolverato, G., Maithel, S., Bauer, T.W., Marques, H., et al. Presentation and clinical outcomes of choledochal cysts in children and adults: a multi-institutional analysis. JAMA Surg 150 (2015), 577–584.
26. [26] Watanapa, P., Watanapa, W.B., Liver fluke-associated cholangiocarcinoma. Br. J. Surg 89 (2002), 962–970.
27. [27] Sithithaworn, P., Yongvanit, P., Duenngai, K., Kiatsopit, N., Pairojkul, C., Roles of liver fluke infection as risk factor for cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci 21 (2014), 301–308.
28. [28] Sahani, D., Prasad, S.R., Tannabe, K.K., Hahn, P.F., Mueller, P.R., Saini, S., Thorotrast-induced cholangiocarcinoma: case report. Abdom. Imaging 28 (2003), 72–74.
29. [29] Kubo, S., Kinoshita, M., Takemura, S., Tanaka, S., Shinkawa, H., Nishioka, T., et al. Characteristics of printing company workers newly diagnosed with occupational cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci 21 (2014), 809–817.
30. [30] Kobayashi, M., Ikeda, K., Saitoh, S., Suzuki, F., Tsubota, A., Suzuki, Y., et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 88 (2000), 2471–2477.
31. [31] Welzel, T.M., Graubard, B.I., El-Serag, H.B., Shaib, Y.H., Hsing, A.W., Davila, J.A., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin. Gastroenterol. Hepatol 5 (2007), 1221–1228.
32. [32] Donato, F., Gelatti, U., Tagger, A., Favret, M., Ribero, M.L., Callea, F., et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 12 (2001), 959–964.
33. [33] Nagaoka, T., Ohkawa, S., Ito, Y., Tamai, S., Tarao, K., Sugimasa, Y., et al. [A case of minute cholangiocellular carcinoma which was found in the follow-up periods of liver cirrhosis and was indistinguishable from hepatocellular carcinoma on hepatic angiography]. Nihon Shokakibyo Gakkai Zasshi 88 (1991), 1369–1374.
34. [34] Li, H., Hu, B., Zhou, Z.Q., Guan, J., Zhang, Z.Y., Zhou, G.W., Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies. World J. Surg. Oncol, 13, 2015, 161.
35. [35] Lee, C.H., Chang, C.J., Lin, Y.J., Yeh, C.N., Chen, M.F., Hsieh, S.Y., Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br. J. Cancer 100 (2009), 1765–1770.
36. [36] Peng, N.F., Li, L.Q., Qin, X., Guo, Y., Peng, T., Xiao, K.Y., et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann. Surg. Oncol 18 (2011), 1258–1266.
37. [37] Michelotti, G.A., Machado, M.V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol 10 (2013), 656–665.
38. [38] Shaib, Y.H., El-Serag, H.B., Davila, J.A., Morgan, R., McGlynn, K.A., Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128 (2005), 620–626.
39. [39] Ye, X.H., Huai, J.P., Ding, J., Chen, Y.P., Sun, X.C., Smoking, alcohol consumption, and the risk of extrahepatic cholangiocarcinoma: a meta-analysis. World J. Gastroenterol 19 (2013), 8780–8788.
40. [40] Palmer, W.C., Patel, T., Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J. Hepatol 57 (2012), 69–76.
41. [41] Welzel, T.M., Graubard, B.I., Zeuzem, S., El-Serag, H.B., Davila, J.A., McGlynn, K.A., Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54 (2011), 463–471.
42. [42] Shaib, Y.H., El-Serag, H.B., Nooka, A.K., Thomas, M., Brown, T.D., Patt, Y.Z., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am. J. Gastroenterol 102 (2007), 1016–1021.
43. [43] Brown, K.M., Parmar, A.D., Geller, D.A., Intrahepatic cholangiocarcinoma. Surg. Oncol. Clin. N. Am 23 (2014), 231–246.
44. [44] Shinojima, Y., Toma, Y., Terui, T., Sweet syndrome associated with intrahepatic cholangiocarcinoma producing granulocyte colony-stimulating factor. Br. J. Dermatol 155 (2006), 1103–1104.
45. [45] Scully, C., Barrett, W.A., Gilkes, J., Rees, M., Sarner, M., Southcott, R.J., Oral acanthosis nigricans, the sign of Leser-Trelat and cholangiocarcinoma. Br. J. Dermatol 145 (2001), 506–507.
46. [46] Nakeeb, A., Pitt, H.A., Sohn, T.A., Coleman, J., Abrams, R.A., Piantadosi, S., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg 224 (1996), 463–473.
47. [47] Chalasani, N., Baluyut, A., Ismail, A., Zaman, A., Sood, G., Ghalib, R., et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31 (2000), 7–11.
48. [48] Patel, A.H., Harnois, D.M., Klee, G.G., LaRusso, N.F., Gores, G.J., The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol 95 (2000), 204–207.
49. [49] Tamandl, D., Herberger, B., Gruenberger, B., Puhalla, H., Klinger, M., Gruenberger, T., Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann. Surg. Oncol 15 (2008), 2787–2794.
50. [50] Maithel, S.K., Gamblin, T.C., Kamel, I., Corona-Villalobos, C.P., Thomas, M., Pawlik, T.M., Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer 119 (2013), 3929–3942.
51. [51] Valls, C., Guma, A., Puig, I., Sanchez, A., Andia, E., Serrano, T., et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom. Imaging 25 (2000), 490–496.
52. [52] Kim, S.A., Lee, J.M., Lee, K.B., Kim, S.H., Yoon, S.H., Han, J.K., et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern – correlation with clinicopathologic findings. Radiology 260 (2011), 148–157.
53. [53] Ciresa, M., De Gaetano, A.M., Pompili, M., Saviano, A., Infante, A., Montagna, M., et al. Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features. Eur. Rev. Med. Pharmacol. Sci 19 (2015), 2786–2797.
54. [54] Ringe, K.I., Wacker, F., Radiological diagnosis in cholangiocarcinoma: Application of computed tomography, magnetic resonance imaging, and positron emission tomography. Best Pract. Res. Clin. Gastroenterol 29 (2015), 253–265.
55. [55] Edge, S.B., Compton, C.C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol 17 (2010), 1471–1474.
56. [56] Ali, S.M., Clark, C.J., Mounajjed, T., Wu, T.T., Harmsen, W.S., Reid-Lombardo, K.M., et al. Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: the Mayo Clinic experience. HPB (Oxford) 17 (2015), 244–250.
57. [57] Weber, S.M., Ribero, D., O'Reilly, E.M., Kokudo, N., Miyazaki, M., Pawlik, T.M., Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17 (2015), 669–680.
58. [58] Joseph, S., Connor, S., Garden, O.J., Staging laparoscopy for cholangiocarcinoma. HPB (Oxford) 10 (2008), 116–119.
59. [59] Goere, D., Wagholikar, G.D., Pessaux, P., Carrere, N., Sibert, A., Vilgrain, V., et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg. Endosc 20 (2006), 721–725.
60. [60] Nagino, M., Kamiya, J., Nishio, H., Ebata, T., Arai, T., Nimura, Y., Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann. Surg 243 (2006), 364–372.
61. [61] Hemming, A.W., Reed, A.I., Howard, R.J., Fujita, S., Hochwald, S.N., Caridi, J.G., et al. Preoperative portal vein embolization for extended hepatectomy. Ann. Surg 237 (2003), 686–691.
62. [62] Sakamoto, Y., Shimada, K., Nara, S., Esaki, M., Kajiwara, T., Arai, Y., et al. Risk factors for early bilirubinemia after major hepatectomy for perihilar cholangiocarcinoma with portal vein embolization. Hepatogastroenterology 57 (2010), 22–28.
63. [63] Yi, B., Xu, A.M., Lai, E.C., Qu, Z.Q., Cheng, Q.B., Liu, C., et al. Preoperative portal vein embolization for hilar cholangiocarcinoma – a comparative study. Hepatogastroenterology 57 (2010), 1341–1346.
64. [64] Dodson, R.M., Weiss, M.J., Cosgrove, D., Herman, J.M., Kamel, I., Anders, R., et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J. Am. Coll. Surg 217 (2013), 736–750 e734.
65. [65] Spolverato, G., Vitale, A., Cucchetti, A., Popescu, I., Marques, H.P., Aldrighetti, L., et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. Cancer, 2015, 10.1002/cncr.29619 Epub ahead of print.
66. [66] Tan, J.C., Coburn, N.G., Baxter, N.N., Kiss, A., Law, C.H., Surgical management of intrahepatic cholangiocarcinoma – a population-based study. Ann. Surg. Oncol 15 (2008), 600–608.
67. [67] Ercolani, G., Dazzi, A., Giovinazzo, F., Ruzzenente, A., Bassi, C., Guglielmi, A., et al. Intrahepatic, peri-hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors?. Eur. J. Surg. Oncol 41 (2015), 1162–1169.
68. [68] de Jong, M.C., Nathan, H., Sotiropoulos, G.C., Paul, A., Alexandrescu, S., Marques, H., et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J. Clin. Oncol 29 (2011), 3140–3145.
69. [69] Endo, I., Gonen, M., Yopp, A.C., Dalal, K.M., Zhou, Q., Klimstra, D., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg 248 (2008), 84–96.
70. [70] Bergeat, D., Sulpice, L., Rayar, M., Edeline, J., Merdignac, A., Meunier, B., et al. Extended liver resections for intrahepatic cholangiocarcinoma: friend or foe?. Surgery 157 (2015), 656–665.
71. [71] Ribero, D., Pinna, A.D., Guglielmi, A., Ponti, A., Nuzzo, G., Giulini, S.M., et al. surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch. Surg 147 (2012), 1107–1113.
72. [72] Carpizo, D.R., D'Angelica, M., Management and extent of resection for intrahepatic cholangiocarcinoma. Surg. Oncol. Clin. N. Am 18 (2009), 289–305.
73. [73] Farges, O., Fuks, D., Le Treut, Y.P., Azoulay, D., Laurent, A., Bachellier, P., et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 117 (2011), 2170–2177.
74. [74] Yamamoto, M., Takasaki, K., Yoshikawa, T., Extended resection for intrahepatic cholangiocarcinoma in Japan. J. Hepatobiliary Pancreat. Surg 6 (1999), 117–121.
75. [75] Spolverato, G., Yakoob, M.Y., Kim, Y., Alexandrescu, S., Marques, H.P., Lamelas, J., et al. Impact of complications on long-term survival after resection of intrahepatic cholangiocarcinoma. Cancer 121 (2015), 2730–2739.
76. [76] Puhalla, H., Schuell, B., Pokorny, H., Kornek, G.V., Scheithauer, W., Gruenberger, T., Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am. J. Surg 189 (2005), 173–177.
77. [77] Paik, K.Y., Jung, J.C., Heo, J.S., Choi, S.H., Choi, D.W., Kim, Y.I., What prognostic factors are important for resected intrahepatic cholangiocarcinoma?. J. Gastroenterol. Hepatol 23 (2008), 766–770.
78. [78] Mavros, M.N., Economopoulos, K.P., Alexiou, V.G., Pawlik, T.M., Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149 (2014), 565–574.
79. [79] Weber, S.M., Jarnagin, W.R., Klimstra, D., DeMatteo, R.P., Fong, Y., Blumgart, L.H., Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J. Am. Coll. Surg 193 (2001), 384–391.
80. [80] Spolverato, G., Yakoob, M.Y., Kim, Y., Alexandrescu, S., Marques, H.P., Lamelas, J., et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma. Ann. Surg. Oncol, 2015, 10.1245/s10434-015-4472-9 Epub ahead of print.
81. [81] Hasegawa, S., Ikai, I., Fujii, H., Hatano, E., Shimahara, Y., Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J. Surg 31 (2007), 1256–1263.
82. [82] Zhu, A.X., Knox, J.J., Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues. Oncologist 17 (2012), 1504–1507.
83. [83] Spolverato, G., Kim, Y., Alexandrescu, S., Marques, H.P., Lamelas, J., Aldrighetti, L., et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann. Surg. Oncol, 2015, 10.1245/s10434-015-4642-9 Epub ahead of print.
84. [84] Bridgewater, J., Galle, P.R., Khan, S.A., Llovet, J.M., Park, J.W., Patel, T., et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol 60 (2014), 1268–1289.
85. [85] Fu, B.S., Zhang, T., Li, H., Yi, S.H., Wang, G.S., Xu, C., et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience. Eur. Surg. Res 47 (2011), 218–221.
86. [86] Sotiropoulos, G.C., Kaiser, G.M., Lang, H., Molmenti, E.P., Beckebaum, S., Fouzas, I., et al. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. Transplant. Proc 40 (2008), 3194–3195.
87. [87] Hong, J.C., Jones, C.M., Duffy, J.P., Petrowsky, H., Farmer, D.G., French, S., et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch. Surg 146 (2011), 683–689.
88. [88] Sapisochin, G., Rodriguez de Lope, C., Gastaca, M., Ortiz de Urbina, J., Suarez, M.A., Santoyo, J., et al. “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?. Am. J. Transplant 14 (2014), 660–667.
89. [89] Sapisochin, G., de Lope, C.R., Gastaca, M., de Urbina, J.O., Lopez-Andujar, R., Palacios, F., et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann. Surg 259 (2014), 944–952.
90. [90] Boehm, L.M., Jayakrishnan, T.T., Miura, J.T., Zacharias, A.J., Johnston, F.M., Turaga, K.K., et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J. Surg. Oncol 111 (2015), 213–220.
91. [91] Sasaki, Y., Imaoka, S., Kasugai, H., Fujita, M., Kawamoto, S., Ishiguro, S., et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60 (1987), 1194–1203.
92. [92] Scheuermann, U., Kaths, J.M., Heise, M., Pitton, M.B., Weinmann, A., Hoppe-Lotichius, M., et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma – a single-center experience. Eur. J. Surg. Oncol 39 (2013), 593–600.
93. [93] Wu, Z.F., Zhang, H.B., Yang, N., Zhao, W.C., Fu, Y., Yang, G.S., Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series. Eur. J. Surg. Oncol 38 (2012), 602–610.
94. [94] Park, S.Y., Kim, J.H., Yoon, H.J., Lee, I.S., Yoon, H.K., Kim, K.P., Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin. Radiol 66 (2011), 322–328.
95. [95] Poggi, G., Amatu, A., Montagna, B., Quaretti, P., Minoia, C., Sottani, C., et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc. Intervent. Radiol 32 (2009), 1187–1192.
96. [96] Kuhlmann, J.B., Euringer, W., Spangenberg, H.C., Breidert, M., Blum, H.E., Harder, J., et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur. J. Gastroenterol. Hepatol 24 (2012), 437–443.
97. [97] Kim, J.H., Won, H.J., Shin, Y.M., Kim, K.A., Kim, P.N., Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. Am. J. Roentgenol 196 (2011), W205–W209.
98. [98] Han, K., Ko, H.K., Kim, K.W., Won, H.J., Shin, Y.M., Kim, P.N., Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J. Vasc. Interv. Radiol 26 (2015), 943–948.
99. [99] Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (2002), 1685–1695.
100. [100] Neoptolemos, J.P., Moore, M.J., Cox, T.F., Valle, J.W., Palmer, D.H., McDonald, A.C., et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308 (2012), 147–156.
101. [101] Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med 362 (2010), 1273–1281.
102. [102] Okusaka, T., Ojima, H., Morizane, C., Ikeda, M., Shibata, T., Emerging drugs for biliary cancer. Expert Opin. Emerg. Drugs 19 (2014), 11–24.
103. [103] Hezel, A.F., Zhu, A.X., Systemic therapy for biliary tract cancers. Oncologist 13 (2008), 415–423.
104. [104] Hezel, A.F., Deshpande, V., Zhu, A.X., Genetics of biliary tract cancers and emerging targeted therapies. J. Clin. Oncol 28 (2010), 3531–3540.
105. [105] Zhu, A.X., Borger, D.R., Kim, Y., Cosgrove, D., Ejaz, A., Alexandrescu, S., et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann. Surg. Oncol 21 (2014), 3827–3834.
106. [106] Zhu, A.X., Hezel, A.F., Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology 53 (2011), 695–704.
107. [107] Lee, J., Park, S.H., Chang, H.M., Kim, J.S., Choi, H.J., Lee, M.A., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13 (2012), 181–188.